Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | RPA1 | P27694 | 10/20 | 0.49 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995581 | 0.87 | RXRA (0.40) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL14995625 | 0.86 | KMT2A (0.54) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL15004255 | 0.86 | KMT2A (0.56) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL15004341 | 0.83 | CCKAR (0.38) | MEN1KMT2AATMRPA1SMN1; SMN2 | |
| SCHEMBL14995433 | 0.82 | KMT2A (0.62) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL15004320 | 0.82 | KMT2A (0.52) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL1765012 | 0.80 | PPP1CA (0.71) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL1526212 | 0.79 | RPA1 (0.61) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL16921426 | 0.79 | RPA1 (0.58) | MEN1KMT2AATMRPA1PPP1CA | |
| SCHEMBL14995535 | 0.78 | KMT2A (0.57) | MEN1KMT2AATMRPA1PPP1CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296720-B2 | Carboxamide-substituted heteroaryl-pyrazoles and the use thereof | AICURIS GMBH & CO. KG (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296720-B2 | Carboxamide-substituted heteroaryl-pyrazoles and the use thereof | AICURIS GMBH & CO. KG (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296720-B2 | Carboxamide-substituted heteroaryl-pyrazoles and the use thereof | AICURIS GMBH & CO. KG (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
| EP-2785705-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013079586-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079586-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | PAICS, AADAC, TPMT | MEN1 2710/4885KMT2A 621/4885ATM 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.